Curative Oncology and Rare Disease Therapies Transforming the Global Biologics Market, 2020–2024

Curative Oncology and Rare Disease Therapies Transforming the Global Biologics Market, 2020–2024

Strategic Collaborations with Specialty Bio-CDMOs will Continue to Drive Growth Opportunities in Antibody-drug Conjugates and Gene Therapies

RELEASE DATE
24-Jul-2020
REGION
North America
Research Code: MEAA-01-00-00-00
SKU: HC03303-GL-MT_24493

$4,950.00

Special Price $4,207.50 save 15 %

In stock
SKU
HC03303-GL-MT_24493

$4,950.00

$4,207.50 save 15 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

With this research service, Frost & Sullivan’s Transformational Health team provides critical insights into the global biologics industry highlighting the growth opportunities, market revenue segmentation, and technology trends influencing its growth. The global biologics market covered in this study includes 4 major segments – antibody therapies, recombinant proteins, vaccines, and regenerative medicine. The forecast for the global biologics market till 2024 reveals interesting trend and paradigm shifts that are set to take place in the industry. Importantly, the study also identifies actionable growth opportunities for industry participants to profit upon.

This research service identifies the largest revenue-generating segments and key therapeutic areas for the global biologics industry. Accelerated regulatory approvals for biologic products and the emergence of next-generation technologies are highlighted, in addition to their influence on market trends during the forecast period. The study highlights the dynamics of the biologics industry and the sub-segments of the biologics market. Growth opportunities in antibody-drug conjugate (ADC), RNA therapy, and gene therapy platforms are also explored. Further, the study discusses the impact (such as the accelerated development of vaccines) of the COVID-19 pandemic on the biologics industry and the market. Current challenges facing the biologics industry such as the sluggish growth rate of vaccines, and recombinant proteins are discussed. Most importantly, this research service discusses possible future market trends such as the accelerated development of mRNA-based vaccines and the increasing importance of specialty bio-CDMOs for the development and commercialization of regenerative medicine. Based on the market trends and revenue forecasts, Frost & Sullivan’s group of analysts highlight key growth opportunities in ADC, RNA, and gene therapy platforms through successful drug launches such as Belantamab Malfodotin, Inclisiran, and Zolgensma.


Research Highlights

Highlights of the report include:

  • Market revenue forecast for the global biologics market till 2024
  • Segment-wise revenue forecast of the top market players and key therapeutic areas
  • Top 3 predictions for the global biologics market
  • Technology trends influencing the future outlook of the biologics market
  • Growth opportunities in the global biologics market
  • Strategic recommendations for the biologics market
  • COVID-19 impact analysis on the biologics market

Key Issues Addressed

  • What will be the revenue and growth rate for the global biologics market from 2020 to 2024?
  • What will be the major segments influencing this revenue and growth rate?
  • What are the key technologies and trends to watch for during the forecast period?
  • What are the major growth opportunities in the biologics industry?
  • What are the top predictions for the biologics market?

RESEARCH: INFOGRAPHIC

This infographic presents a brief overview of the research, and highlights the key topics discussed in it.
Click image to view it in full size

Table of Contents

Purpose of this Study

Methodology

5-step Process to Transformational Growth

Key Findings

Key Questions this Study will Answer

Market Engineering Measurements

Transformation in the Industry Ecosystem

Macro Trends—Biologics Discovery, Development and Manufacturing

Technology Trends—Biologics Discovery, Development and Manufacturing

5 Big Themes for the Global Biologics Market

Strategic Imperatives for the Biologics Market

Scope

Market Segmentation

Description of Main Product Categories

Characteristics of Biologics

Lifecycle of Biologics Products

Market Drivers and Restraints

Key Biologics Companies

Biologics R&D Expenditure

Regulatory Framework for Biologics Approval

Region-wise Regulatory Drug Approval Trends

Key Issues in Market Entry for Regenerative Medicine

Top-level Impact of COVID-19 Pandemic on the Biologics Market

Biologics Manufacturing and Supply Line Challenges

Biologics Pipeline Targeting COVID-19 (SARS-COV-2)

Revenue Forecast—COVID-19 Impact Methodology

Growth Opportunities Critical for Future Success in a Post-pandemic Biologics Market

Companies to Action

Strategic Imperatives for Companies in Light of COVID-19

Methodology

Market Engineering Measurements

Revenue Forecast—Pre-COVID-19 vs. Post-COVID-19 Impact

Product Segmentation

Total Biologics Market—Top 10 Products

Breakdown by Therapeutic Area

Changing Dynamics

Percent Revenue Forecast by Product Type

Antibody Therapies—Overview of Top 10 Products

Market Engineering Measurements

Revenue Forecast

Revenue Forecast Discussion

Anticipated Key Product Launches

Changing Dynamics

Technology Trends in the Antibody Therapy Platform

Recombinant Proteins—Overview of Top 10 Products

Market Engineering Measurements

Revenue Forecast

Revenue Forecast Discussion

Anticipated Key Product Launches

Changing Dynamics

Vaccines—Overview of Top 10 Products

Market Engineering Measurements

Revenue Forecast

Revenue Forecast Discussion

Anticipated Key Product Launches

Changing Dynamics

Cell & Gene Therapy—Overview of Top 10 Products

Market Engineering Measurements

Revenue Forecast

Revenue Forecast Discussion

Technology Trends in the Cell Therapy Platform

Anticipated Key Product Launches

Changing Dynamics

Technology Trends in RNA and Viral Vector Platforms

Roche AG

AMGEN

Sanofi

AbbVie

Novo Nordisk

Merck

Pfizer

Johnson & Johnson

Eli Lilly

GlaxoSmithKline

Major Growth Opportunities

Growth Opportunity 1—ADCs/Polyclonal Antibodies

The Future Trends in Antibody Therapy

ADC Pipeline Analysis

ADCs—Need for Outsourcing

Bio-CDMO Benchmarking—ADC Development and Manufacturing Services

Growth Opportunity 2—RNA-based Therapies & Vaccines

Strategic Imperatives for Better Vaccines

RNA Therapy Pipeline Analysis and Industry Partnerships

mRNA Technology set to Revolutionize Vaccine Therapies

Growth Opportunity 3—Gene Therapy Advancements

Investments & Partnerships Advancing CRISPR/Cas Gene Editing Technology

Gene Therapy—Collaborations and Partnerships

CDMOs to Drive the Growth of Gene Therapy

Growth Opportunity Matrix

Market Engineering Methodology

List of Key Companies Included in this Research Service

List of Exhibits

List of Exhibits (continued)

List of Exhibits (continued)

List of Exhibits (continued)

Related Research
With this research service, Frost & Sullivans Transformational Health team provides critical insights into the global biologics industry highlighting the growth opportunities, market revenue segmentation, and technology trends influencing its growth. The global biologics market covered in this study includes 4 major segments – antibody therapies, recombinant proteins, vaccines, and regenerative medicine. The forecast for the global biologics market till 2024 reveals interesting trend and paradigm shifts that are set to take place in the industry. Importantly, the study also identifies actionable growth opportunities for industry participants to profit upon. This research service identifies the largest revenue-generating segments and key therapeutic areas for the global biologics industry. Accelerated regulatory approvals for biologic products and the emergence of next-generation technologies are highlighted, in addition to their influence on market trends during the forecast period. The study highlights the dynamics of the biologics industry and the sub-segments of the biologics market. Growth opportunities in antibody-drug conjugate (ADC), RNA therapy, and gene therapy platforms are also explored. Further, the study discusses the impact (such as the accelerated development of vaccines) of the COVID-19 pandemic on the biologics industry and the market. Current challenges facing the biologics industry such as the sluggish growth rate of vaccines, and recombinant proteins are discussed. Most importantly, this research service discusses possible future market trends such as the accelerated development of mRNA-based vaccines and the increasing importance of specialty bio-CDMOs for the development and commercialization of regenerative medicine. Based on the market trends and revenue forecasts, Frost & Sullivans group of analysts highlight key growth opportunities in ADC, RNA, and gene therapy platforms through successful drug launches such as Belantamab Malfodotin, Inclisiran, and Zolgensma.--BEGIN PROMO--

Research Highlights

Highlights of the report include:

  • Market revenue forecast for the global biologics market till 2024
  • Segment-wise revenue forecast of the top market players and key therapeutic areas
  • Top 3 predictions for the global biologics market
  • Technology trends influencing the future outlook of the biologics market
  • Growth opportunities in the global biologics market
  • Strategic recommendations for the biologics market
  • COVID-19 impact analysis on the biologics market

Key Issues Addressed

  • What will be the revenue and growth rate for the global biologics market from 2020 to 2024?
  • What will be the major segments influencing this revenue and growth rate?
  • What are the key technologies and trends to watch for during the forecast period?
  • What are the major growth opportunities in the biologics industry?
  • What are the top predictions for the biologics market?
More Information
No Index No
Podcast No
Author Deepak Jayakumar
Industries Healthcare
WIP Number MEAA-01-00-00-00
Is Prebook No
GPS Codes 9600-B1,9571-B1,99C1-B1,9568-B1,9611-B1